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Background: Cardiopulmonary bypass-related platelet dysfunction can increase the
risk of intra- and post-operative bleeding in children undergoing cardiac surgery. More
accurate laboratory tests that identify acquired platelet abnormalities could allow for rapid
identification of patients at risk of bleeding and provide therapies that could reduce
bleeding and platelet transfusions. We hypothesized that thromboelastography with
platelet mapping (TEG-PM) and multiple electrode impedance aggregometry (MEIA) as
functional measures of platelet function would predict whowill require platelet transfusion.
Our secondary hypothesis was that platelet aggregation at both arachidonic acid (AA)
and adenosine diphosphate (ADP) receptors would correlate between TEG-PM and
MEIA results.
Methods: In this prospective study from August 2013 to December 2015, children from
newborn to 5 years of age with congenital heart disease undergoing cardiopulmonary
bypass had blood samples collected and analyzed at four time points: pre-bypass,
post-bypass, post-operatively on arrival to the Cardiac Intensive Care Unit, and 24 h
after arrival.
Results: Of the 44 patients analyzed, the 10 patients who received peri-operative
platelet transfusion were significantly younger (p = 0.05), had higher STAT (Society
of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery) Mortality
Categories (p < 0.002) and longer cardiopulmonary bypass times (p = 0.02). In
univariate analysis, four variables were associated with peri-operative platelet transfusion:
pre-operative age [OR 0.95 (0.93, 0.98), p = 0.03], cardiopulmonary bypass time [1.5
(1.31, 1.68), p = 0.008], STAT Mortality Category [3.64 (3.40, 3.87), p < 0.001], and
TEG-PM ADP [0.79 (0.65, 0.93), p = 0.04]. ROC analysis demonstrated moderate
predictive value of TEG-PM ADP with AUC of 0.745 (0.59, 0.91). A TEG-PM ADP value of
less than or equal to 21 had 85% sensitivity and 70% specificity for platelet transfusion.
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In the multivariate analysis, only STAT Mortality Category predicted platelet transfusion.
TEG-PM and MEIA results correlated for the AA receptor at all 4 time points, but the
same tests at the ADP receptors did not correlate.
Conclusions: TEG-PM ADP may provide more clinically relevant information regarding
platelet function compared to the MEIA at the ADP receptor in children requiring
cardiopulmonary bypass. There was limited correlation between TEG-PM and MEIA
results which raises a concern about the accuracy of these tests at the ADP receptor.
Lower pre-operative TEG-PM ADP MA may predict intra-operative platelet transfusions;
however, larger studies are needed to determine the utility of TEG-PM and MEIA in
guiding platelet transfusions in this population.
Keywords: thromboelastography, congenital heart disease, post-operative hemorrhage, impedance
aggregometry, cardiopulmonary bypass
INTRODUCTION
Cardiopulmonary bypass in pediatric congenital heart disease
operations causes platelet dysfunction due to shear stress,
changes in receptor expression, and platelet exhaustion due to
activation (1). These acquired platelet abnormalities increase
the risk of post-operative bleeding and transfusion. In the peri-
operative phase, platelet count coupled with clinical data are
used to determine administration of platelets. Unfortunately, in
the absence of bleeding, platelet count alone is not sufficient
to determine risk of bleeding since it does not address platelet
function (2). In a retrospective study examining bleeding
in pediatric patients support on extracorporeal membrane
oxygenation, there was no significant difference in platelet counts
between the patients with severe bleeding and those without (3).
Functional measures of hemostasis such as thromboelastography
(TEG, Haemonetics Corp., Braintree, MA) and Multiple
Electrode Impedance Aggregometry (MEIA, VerumDiagnostica,
Roche, Munich, Germany) may be able to identify acquired
platelet abnormalities and allow for goal-directed therapies that
could reduce bleeding and the need for platelet and other
blood product transfusions. Furthermore, these tests are available
as point-of-care tests allowing rapid results and treatment of
acquired platelet abnormalities. Reducing exposure to blood
products is important since it may improve outcomes (4).
TEG measures viscoelastic changes during clot initialization,
formation, and lysis (5). TEG with platelet mapping (TEG-
PM), a modification of the standard TEG, evaluates platelet
function through direct activation of arachidonic acid (AA) and
adenosine diphosphate (ADP) receptors, with analysis of the
resulting formation of TEG curves. Comparison of these curves
with the standard kaolin activated TEG assay allows for the
quantification of platelet aggregation and inhibition at both AA
and ADP receptors (5). Platelet aggregration results are reported
as a maximum amplitude which refers to the highest point of
the TEG curve and inhibition is reported as a percent (5). MEIA
is a point-of-care test approved for clinical use that evaluates
platelet function which measures the change in impedance due
to aggregate formation in response to an agonist (6). There are
many agonists available, including ADP and AA.
Though ADP and AA receptors are weak agonists for
platelet aggregation, they are essential in amplification and
propagation of initial platelet aggregation in response to either
collagen or thrombin. Inhibition of either one or both may
prevent the formation of an effective hemostatic clot promptly.
Platelets on activation secret stored ADP from dense granules
to further activate and recruit new platelets flowing in the
vicinity of the initial clot formation. Thromboxane A2 is
produced by cyclooxygenase (COX-1) enzyme in the platelets in
response to AA-mediated activation. Thromboxane A2 further
increases platelet aggregation in response to collagen/thrombin
and enhances the activation of new platelets in the vicinity.
Thromboxane A2 has a limited paracrine effect due to its very
short half-life (about 30 s).
There have been many attempts to predict post-operative
bleeding with classic coagulation tests, viscoelastic tests, and
MEIA following cardiopulmonary bypass with mixed results (7–
13). To the best of our knowledge, there have been no studies
attempting to predict peri-operative bleeding in pediatric cardiac
patients combining TEG-PM and MEIA. We hypothesized
that TEG-PM and MEIA as measures of platelet function can
predict platelet transfusion in children undergoing repair of
congenital heart disease using cardiopulmonary bypass. There
have been variable results in studies evaluating TEG-PM and/or
MEIA, but we hypothesize that in combination, these assays
will predict patients who will require platelet transfusion. Our
secondary hypothesis was that platelet aggregation at both AA
and ADP receptors on TEG-PM would correlate with MEIA
results at the same receptors. There have been no studies
to date evaluating the correlation between these two tests in




This prospective, observational study was approved by the
Institutional Review Board at Washington University School
of Medicine in St. Louis, MO (201302093). Between August
2013 and December 2015, newborns to 5-year-old patients
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with congenital heart disease who underwent repair using
cardiopulmonary bypass and with moderate to severe surgical
complexity were eligible. Exclusion criteria were weight <3.5 kg,
mild surgical complexity, ECMO/mechanical circulatory
support before or after the procedure, and underlying
bleeding disorder. All eligible patients were identified and
their parents consented in writing during the pre-operative
visit. Anesthesia and post-operative care were carried per
usual practice.
Blood Sampling
Blood samples were collected for each patient at four time
points: following anesthesia induction, following removal from
cardiopulmonary bypass, post-operatively on arrival to the
Cardiac Intensive Care Unit (CICU), and 24 h after arrival to the
CICU. All samples were obtained from indwelling catheters.
Clinical Data
STAT (Society of Thoracic Surgeons-European Association
for Cardio-Thoracic Surgery) Mortality Categories, which
are a validated measure of cardiac lesion complexity, were
recorded. The STAT Mortality Categories are scores from
1 to 5 assigned to each congenital heart disease procedure
based on predicted mortality (13). We collected clinical data,
including blood product transfusion, chest tube output, urine
output, treatment with medications post-operatively (including
vasoactive drugs), and clinically evident thrombosis. To
estimate significant clinical bleeding, we use peri-operative
platelet transfusion as it is our institutional practice to
transfuse platelets with significant clinical bleeding. Platelet
transfusions ranged from 10 to 15 mL/kg. Platelet transfusions
occurred either intraoperatively or postoperatively. Our
institution did not have a specific platelet transfusion guideline
TABLE 1 | Patient demographics.
Variable Patients not requiring platelet transfusion
(n = 34)
Patients requiring platelet transfusion
(n = 10)
P-value
Age (months), median (IQR) 16 (6, 42) 6 (3, 12) 0.05
Gender: no (%)
Male 19 (55.9%) 8 (80%) 0.27
Female 15 (44.1%) 2 (20%)
Weight (kg), median (IQR) 9 (5.8, 17.7) 7.4 (4.9, 9.9) 0.16
BSA (m2), median (IQR) 0.42 (0.30, 0.60) 0.38 (0.29, 0.43) 0.20
Race: no (%)
Caucasian 28 (82.4%) 9 (90%) 1
African American 2 (5.9%) 0
Other 4 (11.8%) 1 (10%)
Type of CHD: no (%)
Cyanotic 17 (50%) 7 (70%) 0.31
Acyanotic 17 (50%) 3 (30%)
STAT mortality category: no (%)
1 21 (61.8%) 0 <0.0001
2 8 (23.5%) 1 (10%)
3 4 (11.8%) 2 (20%)
4 1 (2.9%) 3 (30%)
5 0 4 (40%)
CPB time (minutes), median (IQR) 82 (59, 109) 125 (94, 141) 0.02
Aortic cross clamp
Time (minutes), median (IQR)
41 (26, 60) 52 (21, 89) 0.4
Pre-operative platelet count, median (IQR) 291 (250, 325) 294 (231, 344) 0.89
Chest tube output (mL/Kg) in the 4 h following
the procedure, median (IQR)
5.20 (3.05, 6.70) 12.45 (6.40, 25.52) 0.002
Intra-operative blood product transfusion
Red blood cells, no (%) 22 (64.7%) 9 (90%) 0.12
Fresh Frozen Plasma, no (%) 22 (64.7%) 8 (80%) 0.31
Cryoprecipitate, no (%) 1 (2.9%) 4 (40%) 0.007
Post-operative blood product transfusion
Red blood cells, no (%) 7 (20.6%) 4 (40%) 0.2
Fresh Frozen Plasma, no (%) 0 2 (20%) 0.05
Cryoprecipitate, no (%) 0 1 (10%) 0.23
BSA, body surface area; CHD, congenital heart disease; CPB, cardiopulmonary bypass. Data presented as either a percentage (%) or as median (interquartile range).
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for cardiac intensive care unit. Intraoperative transfusions
were given based upon the rough estimate of ongoing
surgical site bleeding by the operating surgeons. Platelet
count was not routinely measured intra-operatively for
clinical purposes. The postoperative platelet transfusions
were given based on bleeding from chest tubes and platelet
count though no specific platelet count value was used to
guide transfusion.
Laboratory Analysis
At each of the four time points, the following laboratory
analyses were done: TEG-PM, MEIA, prothrombin time
(PT), international normalized ratio (INR), activated partial
thromboplastin time (PTT), fibrinogen, and complete blood
count (CBC). Except for MEIA, all laboratory analyses were
done in the Core Lab at St. Louis University Children’s
Hospital per their usual protocol. Samples were transported
immediately after being drawn to the Core Lab and run within
1 h. TEG-PM samples were collected in sodium citrate tubes.
MEIA samples were collected in hirudin tubes and were run
within 1 h of collection on the Multiplate R© Analyzer (Verum
Diagnostica, Roche, Munich, Germany). Quality controls and
recalibration were done per manufacturer’s recommendations.
AA and ADP were tested on all samples and increases in
impedance are expressed as area under the curve (AUC) units
(collagen is also an available agonist but was not tested due to
space limitations).
Statistical Analysis
Prior to analysis, we excluded one subject during the pre-
operative period because the results were outliers (>3 SD
above mean). All of the statistical analysis was performed
using either IBM SPSS Statistics (version 23 and 25, 2015)
or R (version 3.4.0). Continuous non-parametric data were
compared using Mann-Whitney U-Test and Wilcoxon signed-
rank test, as appropriate. Fisher’s exact test was used for
categorical variables. To investigate factors associated with
platelet transfusion during the peri-operative period, data
were analyzed using both univariate and multivariate logistic
regression. Our focal variables in these analyses were TEG-
PM and MEIA for ADP and AA receptors. We also tested
for associations between platelet transfusion and weight (kg),
cardiopulmonary bypass and aortic cross clamp duration (mins),
STAT Mortality Categories, and type of congenital heart disease
(cyanotic or acyanotic). Associations were evaluated using
likelihood-ratio tests or Fisher’s exact tests. To determine
TABLE 2 | Laboratory values according to time point and platelet transfusion.
Laboratory test Time point No platelet transfusion Platelet transfusion
Median (IQR) P-value Median (IQR) P-value
TEG-PM
ADP MA (mm)
Pre-operative 43.8 (33.1, 55.2) <0.005 17.5 (9.7, 42.0) 0.6
Intra-operative 13.4 (7.5, 31.6) 8.0 (6.0, 16.1)
Post-operative 17.8 (7.1, 29.8) 12.1 (6.9, 21.9)
24 h post-operative 26.8 (10.1, 34) 16.1 (3.7, 36.8)
TEG-PM
AA MA (mm)
Pre-operative 56.6 (52.1, 60.4) <0.005 44.9 (23.3, 63.1) 0.82
Intra-operative 42.1 (30.4, 50.5) 39.5 (11.5, 51.4)
Post-operative 39.1 (26.6, 48.6) 39.2 (30.5, 50.3)
24 h post-operative 25.2 (14.2, 34) 36.7 (12.5, 60)
TEG-PM ADP
percent inhibition
Pre-operative 39 (16.6, 55.8) <0.005 78.5 (39.4, 88.6) 0.114
Intra-operative 81.3 (59.1, 95) 93 (72.8, 98.3)
Post-operative 85 (53, 99.1) 94.1 (82.2, 100)
24 h post-operative 69.8 (57.2, 98.6) 85.7 (40.9, 100)
TEG-PM AA
percent inhibition
Pre-operative 12 (3.6, 21.9) 0.006 16.1 (11, 48.4) 0.08
Intra-operative 26.7 (15.8, 48.6) 39.8 (25.7, 65.3)
Post-operative 32 (17.4, 54.5) 43.5 (32.6, 66.6)
24 h post-operative 69.8 (25.7, 88.9) 52.7 (16, 90.2)
MEIA ADP (AUC) Pre-operative 45 (33, 57.75) 0.006 48 (34, 54) 0.006
Intra-operative 17.5 (10.3, 37.8) 16 (11, 26)
Post-operative 35.5 (24.3, 53.3) 29 (16, 32)
24 h post-operative 37.5 (26.3, 58) 36 (31, 41)
MEIA AA (AUC) Pre-operative 59 (41, 68.5) <0.005 45 (32, 74) 0.05
Intra-operative 19.5 (11.3, 37.3) 20 (15, 34)
Post-operative 38 (30.5, 49.8) 31 (27, 58)
24 h post-operative 23.5 (17, 34.5) 26 (21, 39)
CPB, cardiopulmonary bypass; TEG-PM, thromboelastography with platelet mapping; ADP, adenosine diphosphate receptor; AA, arachidonic acid receptor; MEIA, multiple electrode
impedance aggregometry; AUC, area under the curve.
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FIGURE 1 | Median values for TEG-PM Inhibition, TEG-PM MA, and MEIA at the ADP and AA receptors for each time point. The blue bars represent test results for
patients who required platelet transfusion and the green bars represent patients who did not require platelet transfusion. Dashed reference lines on inhibition graphs
signifying significant inhibition at 80%. Reference line on MEIA graph signifies 10% of the reference range for children 1–4 years of age (14). TEG-PM,
thromboelastography with platelet mapping; MA, maximum amplitude; ADP, adenosine diphosphate receptor; AA, arachidonic acid receptor; MEIA, multiple electrode
impedance aggregometry; AUC, area under the curve. ◦Outliers (1.5–3x IQR); *Extreme outliers (>3x IQR).
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independent associations, all variables that were significant (two-
sided, p < 0.05) were considered. Due to the low number of
patients receiving platelet transfusions, we were not able to
include all potential confounders. Since our hypothesis included
TEG-PM ADP, we analyzed this variable in a logistic regression
model that adjusted for the covariate that was most strongly
associated with platelet transfusion (STAT Mortality Category).
Data are presented as median (IQR) and odds ratio (95% CI).
A receiver operating characteristic curve (ROC) was created
to establish predictive models for platelet transfusion based
on pre-operative platelet count, TEG-PM ADP and AA as
well as MEIA ADP and AA. The correlation between MEIA
and TEG-PM AA and TEG-PM ADP was assessed using
linear regression.
RESULTS
Forty-seven patients were enrolled in the study. Three patients
were excluded following enrollment: one patient did not require
cardiopulmonary bypass; the second required post-operative
extracorporeal membrane oxygenation support; and the third
was enrolled in another study limiting our ability to obtain the
needed blood samples. Thus, 44 patients were included in the
statistical analyses. Their demographics are displayed in Table 1.
TABLE 3 | Univariate analysis predicting platelet transfusion.
Clinical factors Odds ratio (95% CI) P-value
Age (months) 0.95 (0.93, 0.98) 0.03
Weight (kg) 0.98 (0.78, 1.18) 0.16
Cyanotic heart disease 0.82 (0.58, 1.05) 0.28
CPB time (per 10min) 1.5 (1.31, 1.68) 0.008
STAT mortality category 4 or 5 3.64 (3.40, 3.87) <0.001
Platelet count 0.88 (0.58, 1.17) 0.58
Pre-operative labs*
TEG-PM ADP (mm) 0.79 (0.65, 0.93) 0.04
TEG-PM AA (mm) 0.84 (0.57, 1.11) 0.41
MEIA ADP (AUC) 0.99 (0.81, 1.15) 0.92
MEIA AA (AUC) 0.98 (0.86, 1.10) 0.83
*Pre-operative labs drawn after induction of anesthesia. CPB, cardiopulmonary
bypass; STAT, Society of Thoracic Surgeons-European Association for Cardio-
Thoracic Surgery; TEG-PM, thromboelastography with platelet mapping; ADP, adenosine
diphosphate receptor; AA, arachidonic acid receptor; MEIA, multiple electrode impedance
aggregometry; AUC, area under the curve.
TABLE 4 | Multivariate analysis predicting platelet transfusion.
Predictors of platelet transfusion Odds ratio (95% CI) P-value
STAT mortality category 55.30 (4.5, 981.1) 0.002
Pre-operative TEG-PM ADP 0.98 (0.91, 1.05) 0.52
STAT, Society of Thoracic Surgeons-European Association for Cardio-Thoracic
Surgery; TEG-PM ADP, Thromboelastography with platelet mapping at the adenosine
diphosphate receptor.
Only 10 patients received peri-operative platelet transfusions
(including one was transfused both intra- and post-operatively).
Eight patients (18.2%) received intra-operative platelet
transfusion and three patients (6.8%) received post-operative
platelet transfusion. Comparison of patients who received peri-
operative platelet transfusion with those that did not, revealed a
significant difference in age (p= 0.05), STAT Mortality Category
(p < 0.002), and cardiopulmonary bypass time (p = 0.02)
(Table 1). Patients who received platelet transfusions also had
increased chest tube output (p = 0.002). There was no difference
in pre-operative platelet count, weight, body surface area (BSA,
m2), type of congenital heart disease, or aortic cross clamp
time among patients who received transfusions and those that
did not.
The laboratory values demonstrate decreased platelet function
following cardiopulmonary bypass when compared with pre-
operative values. For patients not requiring transfusion (Table 2),
there was a decrease in median TEG-PM MA results at both the
AA and ADP receptors (p < 0.005 and p < 0.005, respectively)
as well as median MEIA results for both the AA and ADP
receptors (p < 0.005 and p= 0.006, respectively). There was also
a significant increase in inhibition at both AA and ADP receptors
TABLE 5 | Correlation between TEG-PM ADP MA and MEIA ADP AUC.




24 h post-operative 0.012 0.51
TEG-PM, thromboelastography with platelet mapping; ADP, adenosine diphosphate
receptor; MEIA, multiple electrode impedance aggregometry; AUC, area under the curve.
FIGURE 2 | TEG-PM MA vs. MEIA AUC for the ADP Receptor at all sampling
time points. TEG-PM MA, thromboelastography with platelet mapping
maximum amplitude; ADP, adenosine diphosphate receptor; MEIA, multiple
electrode impedance aggregometry; AUC, area under the curve.
Frontiers in Pediatrics | www.frontiersin.org 6 December 2019 | Volume 7 | Article 509
Barker et al. Predict Platelet Transfusion Pediatric CPB
TABLE 6 | Correlation between TEG-PM AA MA and MEIA AA AUC.




24 h post-operative 0.38 <0.0001
TEG-PM, thromboelastography with platelet mapping; AA, arachidonic acid receptor;
MEIA, multiple electrode impedance aggregometry; AUC, area under the curve.
FIGURE 3 | TEG-PM MA vs. MEIA AUC for the AA Receptor at all sampling
time points. TEG-PM MA, thromboelastography with platelet mapping
maximum amplitude; AA, arachidonic acid receptor; MEIA, multiple electrode
impedance aggregometry; AUC, area under the curve.
(p = 0.006 and p < 0.005, respectively). This change was
significant at all three time points when compared to their pre-
operative values. For patients receiving platelet transfusion, the
same pattern existed (Figure 1), but failed to reach significance
except for MEIA AA and ADP receptors (p= 0.05 and p= 0.006,
respectively). This may be due to the small number of patients
that required platelet transfusion or even variability introduced
with transfusions.
Upon univariate analysis, pre-operative age, cardiopulmonary
bypass time, STAT Mortality Category, and TEG-PM ADP,
significantly predicted platelet transfusion (Table 3). Multivariate
analysis indicated that TEG-PM ADP was not independently
associated with platelet transfusion (Table 4). When evaluating
the correlation between TEG-PM and MEIA results, the
correlation was significant for the AA receptor for all
time points; however, at the ADP receptor there was no
correlation between the two tests (Table 5 and Figure 2, Table 6
and Figure 3).
In the ROC analysis, TEG-PM ADP demonstrated moderate
predictive ability with AUC of 0.745 (95% CI 0.587–0.907) and
p-value of 0.02 (Figure 4). A cut off value of less than or equal
to 21mm had a 85% sensitivity and 70% specificity for platelet
transfusion. Platelet count, TEG-PM ADP, MEIA ADP and
MEIA AA were not predictive of platelet transfusion.
FIGURE 4 | ROC Curves. (A) Pre-operative TEG-PM ADP demonstrates
moderate predictive value for platelet transfusion. AUC is 0.75 (0.59, 0.91) with
a p-value of 0.02. A cut off value of less than or equal to 21mm has 85%
sensitivity and 70% specificity for predicting platelet transfusion. (B) Platelet
count. Pre-operative platelet count failed to predict platelet transfusion. AUC is
0.52 (0.30, 0.73) with a p-value of 0.88. TEG-PM ADP, thromboelastography
with platelet mapping adenosine diphosphate receptor maximum amplitude.
DISCUSSION
This is the first study to combine TEG-PM and MEIA results
to predict platelet transfusion in children undergoing repair of
congenital heart disease with cardiopulmonary bypass. Similar to
others, we found that there is a significant reduction in platelet
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function with cardiopulmonary bypass that is quantified by both
TEG-PM and MEIA (9, 10). Although pre-operative TEG-PM
ADP predicted platelet transfusion in univariate analysis and
ROC analysis, it was not significant in the multivariate model.
There have been several adult studies that have utilized
TEG-PM and MEIA to predict post- operative bleeding with
conflicting results. Recently, Agarwal et al. prospectively studied
54 adults undergoing cardiac surgery (7). They demonstrated
significant platelet inhibition on both TEG-PM and MEIA
following cardiopulmonary bypass. However, neither of these
assays correlated with post-operative blood loss. In another
study, Petricevic et al. used thromboelastometry and MEIA
to predict excessive post-operative bleeding in 148 adults
undergoing elective cardiac surgery (15). They found significant
differences at all three time points for the MEIA and
thromboelastometry results between the “bleeders” and “non-
bleeders.” The differences in the results between these two studies
may be due to the larger sample size in the Petricevic study, or
perhaps the difference in outcomes measured in the two studies.
There have also been two studies that evaluated prevention
of post-operative bleeding using TEG- and MEIA-based
guidelines. Weber at al. randomized 100 adults to conventional
care vs. use of point-of-care TEG and MEIA to guide
transfusions (11). This trial showed significant decrease
in the amount of red blood cells, fresh frozen plasma,
and platelets transfused in the point of care group. There
have been few pediatric studies of thromboelastography.
Saini et al. demonstrated severe platelet dysfunction in
patients on extracorporeal membrane oxygenation (3).
In a retrospective review of 150 children with congenital
heart disease requiring cardiopulmonary bypass, Kane et al.
demonstrated a reduction in platelet and cryoprecipitate
transfusions when intraoperative TEG was used to guide
transfusion (12).
Interestingly, our data indicate that there is a moderate
correlation at the AA receptor between TEG-PM and MEIA but
a poor correlation at the ADP receptor. This is consistent with
the results George et al. found in adult trauma patients (16). This
raises the question of which test is more accurate or clinically
relevant at the ADP receptor. Our study suggests TEG-PM
ADP might be more clinically relevant since pre-operative TEG-
PM ADP on univariate analysis was predictive of peri-operative
bleeding and platelet transfusion. Multivariate analysis did not
result in similar findings, therefore additional data are required
to determine which test, if any, can determine clinically relevant
platelet dysfunction.
Because of the small sample size and the low number
of patients receiving platelet transfusions, this study was
underpowered to quantify the putative association between
functional measures of platelet function and subsequent platelet
transfusion. Even so, pre-operative TEG-PM ADP predicted
platelet transfusion in the univariate analysis. A larger study is
needed to either confirm or refute this relationship.
CONCLUSION
TEG-PM ADP MA may provide more clinically relevant
information regarding platelet function compared to the MEIA
at the ADP receptor in children undergoing congenital heart
disease operations with cardiopulmonary bypass. The change
in correlation over time at the AA receptor between platelet
function testing methods suggests post-operative acquired
change in platelet function. Larger studies are needed to
determine the utility of TEG-PM and MEIA in guiding platelet
transfusions in this population.
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